Concepedia

Beverly Moy

BM

Statistics

Publications

123

Citations

9.8K

H-Index

48

Active since

1942

Affiliations

Massachusetts General Hospital(Current)

Harvard University

Dana-Farber Cancer Institute

Brigham and Women's Hospital

University of California, San Francisco

Beverly Moy is an author at Massachusetts General Hospital specializing in medicine, oncology, and breast cancer.

ORCID

Top concepts

Publications per year

1942–2025

123

Publications

123

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Sara M. Tolaney, William T. Barry, Chau T. Dang et al. · New England Journal of Medicine · 2015 · 731 citations · Full text

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng et al. · Journal of Clinical Oncology · 2020 · 588 citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

, , +10

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes et al. · The Lancet Oncology · 2016 · 551 citations

, , +9

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

Rachel A. Freedman, Rebecca Gelman, Carey K. Anders et al. · Journal of Clinical Oncology · 2019 · 332 citations · Full text

Rows per page

1–5 of 123